Q2 2026 Earnings

Revenue

$103.2B+10.1% YoY

Gross Profit

$3.5B3.4% margin

Operating Income

$1.5B1.4% margin

Net Income

$1.1B1.1% margin

EPS (Diluted)

$8.92

QoQ Revenue Growth

+5.4%

Operating Cash Flow

$2.4B

Free Cash Flow

$2.5B

Stock-Based Comp.

Total Assets

$84.2B

Total Liabilities

$84.7B

Stockholders' Equity

-$1.7B

Cash & Equivalents

$4.1B

Metric	Current	Year Ago	Change
Revenue	$103.2B	$93.7B	+10.1%
Gross Profit	$3.5B	$3.1B	+12.6%
Operating Income	$1.5B	$745M	+97.0%
Net Income	$1.1B	$241M	+360.6%

North American Pharmaceutical Segment

$86.5B84%

Oncology And Multispecialty Segment

$12.0B12%

Medical-Surgical Solutions Segment

$2.9B3%

Prescription Technology Solutions Segment

$1.4B1%

Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment

$302M0%